Thyroid Gland Anaplastic Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: THY121 MIFTS: 67	Thyroid Gland Anaplastic Carcinoma Categories: Cancer diseases, Endocrine diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Thyroid Gland Anaplastic Carcinoma

MalaCards integrated aliases for Thyroid Gland Anaplastic Carcinoma:

Name: Thyroid Gland Anaplastic Carcinoma ¹¹ ¹⁴

Anaplastic Thyroid Carcinoma ¹¹ ¹⁹ ⁵⁸ ⁷¹

Thyroid Cancer, Anaplastic ¹⁹ ⁵

Anaplastic Thyroid Cancer ¹⁹ ⁷⁵

Thyroid Carcinoma, Anaplastic ¹⁹

Thyroid Carcinoma Anaplastic ⁵³

Characteristics:

Prevelance:

Anaplastic Thyroid Carcinoma: 1-9/1000000 (Europe, Europe) ⁵⁸

Age Of Onset:

Anaplastic Thyroid Carcinoma: Adult,Elderly ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Endocrine diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Malignant neoplasms of thyroid and other endocrine glands

Malignant neoplasm of thyroid gland

Orphanet: ⁵⁸

Rare endocrine diseases

Sources

Summaries for Thyroid Gland Anaplastic Carcinoma

GARD: ¹⁹ Anaplastic thyroid cancer (ATC) accounts for less than 2% of all thyroid cancers and is the most aggressive type of thyroid cancer. Women are more likely to be affected than men. ATC generally occurs in individuals with a history of goiter or thyroid cancer. A history of head and neck radiation or exposure to radioactive materials may also increase the risk for ATC. Patients with ATC generally present with a rapidly-growing neck mass which may cause trouble swallowing (dysphagia), coughing, neck pain, and trouble breathing (dyspnea). Metastasis is present in more than half of individuals at the time of diagnosis. Patients with metastases may also present with bone pain, lymph node enlargement, weakness, and neurological deficits.

MalaCards based summary: Thyroid Gland Anaplastic Carcinoma, also known as anaplastic thyroid carcinoma, is related to thyroid carcinoma and thyroid cancer, nonmedullary, 1, and has symptoms including dyspnea and hoarseness. An important gene associated with Thyroid Gland Anaplastic Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Signal Transduction and Malignant pleural mesothelioma. The drugs Levoleucovorin and Pemetrexed have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and bone, and related phenotypes are anaplastic thyroid carcinoma and broad neck

Orphanet: ⁵⁸ A disorder that represents the ultimate dedifferentiation step of thyroid tumorigenesis and is one of the most severe cancers in humans.

Disease Ontology: ¹¹ A thyroid gland carcinoma that is composed of undifferentiated cells.

Wikipedia: ⁷⁵ Anaplastic thyroid cancer (ATC), also known as anaplastic thyroid carcinoma, is an aggressive form of... more...

Sources

Related Diseases for Thyroid Gland Anaplastic Carcinoma

Diseases related to Thyroid Gland Anaplastic Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 512)

#	Related Disease	Score	Top Affiliating Genes
1	thyroid carcinoma	32.9	TG RET BRAF
2	thyroid cancer, nonmedullary, 1	32.1	TP53 NKX2-1 BRAF
3	differentiated thyroid carcinoma	32.0	RET PAX8 NKX2-1 BRAF
4	thyroid tumor	31.8	RET PTEN PIK3CA BRAF
5	papillary carcinoma	31.6	TSHR TPO TG RET PAX8 NKX2-1
6	graves disease 1	31.6	TSHR TPO TG CALCA
7	thyroiditis	31.6	TSHR TPO TG RET CALCA
8	thyroid cancer, nonmedullary, 2	31.5	TSHR TG PTEN PAX8 CALCA BRAF
9	thyroid gland follicular carcinoma	31.3	TSHR TPO TP53 TG RET PTEN
10	multinodular goiter	31.3	TSHR TPO TG RET PTEN PAX8
11	hypothyroidism	31.2	TSHR TPO TG RET PAX8 NKX2-1
12	thyroid lymphoma	31.2	TPO TG RET CALCA
13	hypothyroidism, congenital, nongoitrous, 1	31.2	TSHR TG PAX8
14	thyroid carcinoma, familial medullary	31.2	TG RET NKX2-1 CALCA BRAF
15	endocrine gland cancer	31.2	RET MIR34C MIR30A MIR18A MIR17
16	nodular goiter	31.1	TSHR TPO TG RET CALCA BRAF
17	graves' disease	31.1	TSHR TPO TG PAX8
18	hypothyroidism, congenital, nongoitrous, 2	31.1	TSHR TG PAX8 NKX2-1
19	subacute thyroiditis	31.1	TSHR TPO TG
20	adenoma	31.1	TSHR TP53 TG RET PIK3CA CTNNB1
21	thyroid gland medullary carcinoma	31.1	TG RET PAX8 NKX2-1 CALCA
22	endemic goiter	31.1	TSHR TPO TG PAX8 CALCA
23	hyperthyroidism	31.0	TSHR TPO TG CALCA
24	hashimoto thyroiditis	31.0	TSHR TPO TG RET CALCA BRAF
25	squamous cell carcinoma	31.0	TP53 PTEN PIK3CA NKX2-1 CTNNB1 CDH1
26	follicular adenoma	31.0	TSHR TPO TG RET PTEN PAX8
27	melanoma	31.0	TP53 PTEN PIK3CA MIR34C MIR19A MIR17
28	nontoxic goiter	30.9	TSHR TPO TG CALCA
29	substernal goiter	30.9	TG RET CALCA
30	hypoparathyroidism	30.9	TPO RET CALCA
31	gastrointestinal stromal tumor	30.9	TP53 RET PTEN PIK3CA CTNNB1 BRAF
32	lung cancer susceptibility 3	30.8	TP53 PIK3CA NKX2-1 MIR30A MIR17 CTNNB1
33	goiter	30.8	TSHR TPO TG RET PAX8 NKX2-1
34	squamous cell carcinoma, head and neck	30.8	TP53 PTEN PIK3CA MIR30A MIR19A MIR18A
35	endometrial cancer	30.8	TP53 PTEN PIK3CA MIR30A CTNNB1 CDH1
36	papillary thyroid microcarcinoma	30.7	TG NKX2-1 CALCA BRAF
37	acute thyroiditis	30.7	TPO TG CALCA
38	papillary adenocarcinoma	30.7	TP53 TG PAX8 NKX2-1 MIR30A
39	lymphatic system disease	30.7	TP53 MIR34C MIR30A MIR18A MIR17
40	bilateral breast cancer	30.7	TP53 PTEN CDH1
41	lung cancer	30.7	TP53 RET PTEN PIK3CA NKX2-1 MIR34C
42	lipomatosis, multiple	30.7	TP53 PTEN PIK3CA
43	li-fraumeni syndrome	30.7	TP53 PTEN PIK3CA CTNNB1 CDH1
44	hematologic cancer	30.7	MIR34C MIR30A MIR19A MIR18A MIR17
45	cowden syndrome	30.7	TP53 RET PTEN PIK3CA MIR19A CTNNB1
46	mixed cell type cancer	30.7	TP53 PTEN PIK3CA PAX8 CTNNB1 CDH1
47	mucoepidermoid carcinoma	30.7	TG CDH1 CALCA
48	mesothelioma, malignant	30.7	NKX2-1 MIR17 CTNNB1 CDH1
49	leukemia, chronic myeloid	30.7	TP53 PTEN MIR30A MIR19A MIR18A MIR17
50	inherited cancer-predisposing syndrome	30.6	TP53 RET PTEN CDH1

Graphical network of the top 20 diseases related to Thyroid Gland Anaplastic Carcinoma:

Sources

Symptoms & Phenotypes for Thyroid Gland Anaplastic Carcinoma

Human phenotypes related to Thyroid Gland Anaplastic Carcinoma:

⁵⁸ ³⁰ (show all 23)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	anaplastic thyroid carcinoma ⁵⁸ ³⁰	Obligate (100%)	Obligate (100%)	HP:0011779
2	broad neck ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000475
3	hoarse voice ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001609
4	nodular goiter ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0005994
5	dysphagia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002015
6	vocal cord paralysis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001605
7	neoplasm of the lung ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0100526
8	respiratory distress ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002098
9	lymphadenopathy ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002716
10	upper airway obstruction ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002781
11	pain ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0012531
12	laryngotracheal stenosis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0004894
13	dysphonia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001618
14	hemoptysis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002105
15	cough ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0012735
16	weight loss ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001824
17	stridor ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0010307
18	neoplasm of the skeletal system ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0010622
19	abnormal skeletal muscle morphology ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0011805
20	tracheoesophageal fistula ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0002575
21	malignant neoplasm of the central nervous system ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0100836
22	dyspnea ⁵⁸		Occasional (29-5%)
23	goiter ⁵⁸		Very frequent (99-80%)

UMLS symptoms related to Thyroid Gland Anaplastic Carcinoma:

dyspnea; hoarseness

MGI Mouse Phenotypes related to Thyroid Gland Anaplastic Carcinoma:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	normal	MP:0002873	10.2	ADGRE5 BRAF CALCA CDH1 CTNNB1 MIR18A
2	neoplasm	MP:0002006	10.18	BRAF CALCA CDH1 CTNNB1 NKX2-1 PIK3CA
3	endocrine/exocrine gland	MP:0005379	10.1	BRAF CDH1 CTNNB1 NKX2-1 PAX8 PIK3CA
4	limbs/digits/tail	MP:0005371	10.06	BRAF CTNNB1 PAX8 PTEN RET TG
5	no phenotypic analysis	MP:0003012	10.03	ADGRE5 CDH1 CTNNB1 NKX2-1 PAX8 PIK3CA
6	hearing/vestibular/ear	MP:0005377	9.97	BRAF CALCA CTNNB1 PAX8 TG TP53
7	embryo	MP:0005380	9.91	BRAF CALCA CDH1 CTNNB1 PAX8 PIK3CA
8	digestive/alimentary	MP:0005381	9.81	BRAF CDH1 CTNNB1 NKX2-1 PIK3CA PTEN
9	reproductive system	MP:0005389	9.7	BRAF CDH1 CTNNB1 NKX2-1 PAX8 PIK3CA
10	skeleton	MP:0005390	9.36	BRAF CALCA CTNNB1 NKX2-1 PAX8 PIK3CA

Sources

Drugs & Therapeutics for Thyroid Gland Anaplastic Carcinoma

Drugs for Thyroid Gland Anaplastic Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Levoleucovorin

Approved, Experimental, Investigational

Phase 2

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Pemetrexed

Approved, Investigational

Phase 2

150399-23-8, 137281-23-3

60843 446556 135565230

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Fluorouracil

Approved

Phase 2

51-21-8

3385

Hydroxyurea

Approved

Phase 2

127-07-1

3657

Atezolizumab

Approved, Investigational

Phase 2

1380723-44-3

Vemurafenib

Approved

Phase 2

918504-65-1

42611257

Dabrafenib

Approved, Investigational

Phase 2

1195765-45-7

44462760

Fludarabine

Approved

Phase 2

75607-67-9, 21679-14-1

30751 657237

Aldesleukin

Approved

Phase 2

110942-02-4

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Cemiplimab

Approved, Investigational

Phase 2

1801342-60-8

Nivolumab

Approved

Phase 2

946414-94-4

Ipilimumab

Approved

Phase 2

477202-00-9

Benzocaine

Approved, Investigational

Phase 2

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 2

1401-55-4

16129878 16129778

Pembrolizumab

Approved

Phase 2

1374853-91-4

254741536

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

135329020

Lenvatinib

Approved, Investigational

Phase 2

417716-92-8

9823820

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Cisplatin

Approved

Phase 1, Phase 2

15663-27-1

2767 5702198 441203

Lenograstim

Approved, Investigational

Phase 1, Phase 2

135968-09-1

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 2

59-30-3

6037

Spartalizumab

Investigational

Phase 1, Phase 2

1935694-88-4

Efatutazone

Investigational

Phase 1, Phase 2

223132-37-4

9832447

Folic Acid Antagonists

Phase 2

Folate

Phase 2

Vitamin B9

Phase 2

Vitamin B Complex

Phase 2

Antimetabolites

Phase 2

Immunoglobulins, Intravenous

Phase 2

Immunoglobulins

Phase 2

Immunoglobulin G

Phase 2

Antibodies, Monoclonal

Phase 2

Antibodies

Phase 2

Immunologic Factors

Phase 2

Endothelial Growth Factors

Phase 2

Mitogens

Phase 2

Antibodies, Bispecific

Phase 2

Alkylating Agents

Phase 2

Antiviral Agents

Phase 2

Anti-Retroviral Agents

Phase 2

Antineoplastic Agents, Alkylating

Phase 2

Anti-Infective Agents

Phase 2

Interleukin-2

Phase 2

Anti-HIV Agents

Phase 2

Analgesics, Non-Narcotic

Phase 2

Analgesics

Phase 2

Immunosuppressive Agents

Phase 2

Interventional clinical trials:

(show top 50) (show all 54)

#	Name	Status	NCT ID	Phase	Drugs
1	A Phase II/III Study to Evaluate the Safety and Efficacy of Combretastatin A-4 Phosphate in Combination With Paclitaxel and Carboplatin in Comparison With Paclitaxel and Carboplatin Against Anaplastic Thyroid Carcinoma [FACT]	Terminated	NCT00507429	Phase 2, Phase 3	CA4P;paclitaxel;carboplatin
2	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Fosbretabulin Tromethamine (CA4P) in Combination With Paclitaxel and Carboplatin in Anaplastic Thyroid Carcinoma (FACT2)	Withdrawn	NCT01701349	Phase 3	Fosbretabulin + paclitaxel + carboplatin;Placebo + paclitaxel + carboplatin
3	Prospective Study of Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer	Unknown status	NCT03565536	Phase 2	Nexavar
4	Phase 2 Trial of Pemetrexed (Alimta™) Combined With Paclitaxel in Patients With Recurrent/Advanced Follicular, Papillary or Anaplastic Thyroid Cancer	Unknown status	NCT00786552	Phase 2	pemetrexed + paclitaxel
5	A Multi-center, Single-arm, Open-label Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Sorafenib in Japanese Patients With Anaplastic Thyroid Carcinoma or Locally Advanced or Metastatic Medullary Thyroid Carcinoma	Completed	NCT02114658	Phase 2	Sorafenib (Nexavar,BAY43-9006)
6	A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer	Completed	NCT00625846	Phase 2	Pazopanib Hydrochloride
7	A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer	Completed	NCT01236547	Phase 2	Paclitaxel;Pazopanib Hydrochloride
8	Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer (HOPE)	Completed	NCT02726503	Phase 2	Lenvatinib
9	Phase 2 Study of Pembrolizumab Combined With Chemoradiation Therapy in Anaplastic Thyroid Cancer	Completed	NCT03211117	Phase 2	Docetaxel;Doxorubicin Hydrochloride
10	A Multicenter Phase II Study of Intensified Concomitant Chemoradiotherapy for Patients With Anaplastic Thyroid Cancer	Completed	NCT00004089	Phase 2	fluorouracil;hydroxyurea;paclitaxel
11	A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)	Completed	NCT01240590	Phase 1, Phase 2	Crolibulin;Cisplatin
12	Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Cancer	Completed	NCT00654238	Phase 2	sorafenib
13	Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/ Undifferentiated Thyroid Cancer	Completed	NCT02688608	Phase 2	Pembrolizumab
14	Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies	Completed	NCT02404441	Phase 1, Phase 2
15	Phase II Trial Of Combretastatin A-4 Phosphate (CA4P) In Advanced Anaplastic Carcinoma Of The Thyroid	Completed	NCT00060242	Phase 2	fosbretabulin disodium
16	Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas	Recruiting	NCT03181100	Phase 2	Atezolizumab;Cobimetinib;Nab-paclitaxel;Paclitaxel;Vemurafenib
17	Lenvatinib in Combination With Pembrolizumab for Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer	Recruiting	NCT04171622	Phase 2	Lenvatinib
18	A Phase II, Multicenter Study of XmAb20717 in Patients With Metastatic Anaplastic Thyroid Cancer With an Exploratory Cohort in Aggressive Hurthle Cell Thyroid Cancer	Recruiting	NCT05453799	Phase 2	Vudalimab
19	Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer (ANAPLAST-NEO)	Recruiting	NCT04739566	Phase 2	Dabrafenib;Trametinib
20	Pembrolizumab in Combination With Dabrafenib and Trametinib as a Neoadjuvant Strategy Prior to Surgery in BRAF-Mutated Anaplastic Thyroid Cancer	Recruiting	NCT04675710	Phase 2	Dabrafenib;Trametinib
21	Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers	Recruiting	NCT04759911	Phase 2	Selpercatinib
22	Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types	Recruiting	NCT03449108	Phase 2	Cyclophosphamide;Fludarabine
23	A Pilot Study of the Addition of Cemiplimab, an Antibody to PD-1, to the Treatment of Subjects With BRAF-Mutant Anaplastic Thyroid Cancer Who Are No Longer Responding to Dabrafenib and Trametinib	Recruiting	NCT04238624	Phase 2	Dabrafenib;Trametinib
24	An Open Label, Multicenter Phase Ib/II Clinical Study to Evaluate Efficacy , Safety and PK of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation	Recruiting	NCT05102292	Phase 1, Phase 2	HLX208
25	An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors	Recruiting	NCT04579757	Phase 1, Phase 2	Surufatinib and Tislelizumab _ Part 1;Surufatinib and Tislelizumab _ Part 2
26	Exploratory Basket Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. CABATEN Study	Recruiting	NCT04400474	Phase 2	Cabozantinib 40 mg
27	Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer	Recruiting	NCT05119296	Phase 2	Pembrolizumab (Keytruda)
28	A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors, With Emphasis on Squamous Cell Carcinoma of the Head and Neck, Triple Negative Breast Cancer, Anaplastic Thyroid Carcinoma, and Cutaneous Squamous Cell Carcinoma	Active, not recruiting	NCT04592484	Phase 1, Phase 2
29	A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer	Active, not recruiting	NCT02244463	Phase 2	MLN0128
30	A Phase 2 Study of Nivolumab Plus Ipilimumab in RAI Refractory, Aggressive Thyroid Cancer With Exploratory Cohorts in Medullary and Anaplastic Thyroid Cancer	Active, not recruiting	NCT03246958	Phase 2	Nivolumab;Ipilimumab
31	A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer	Active, not recruiting	NCT02152137	Phase 2	efatutazone;paclitaxel
32	Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer	Active, not recruiting	NCT04552769	Phase 2	Abemaciclib
33	A Single-arm, Open-lable, Multicenter, Phase II Clinical Study of HX008 in Subjects With Anaplastic Thyroid Cancer	Not yet recruiting	NCT04574817	Phase 2	HX008
34	Pembrolizumab in Combination With Standard 1st Line Therapy (Lenvatinib / Chemotherapy) for Locally Advanced or Metastatic Poorly Differentiated or Anaplastic Thyroid Cancer	Suspended	NCT04731740	Phase 2	Lenvatinib;Chemotherapy
35	An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)	Terminated	NCT02657369	Phase 2	Lenvatinib 24 mg
36	Phase 2 Study With Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer	Terminated	NCT00804830	Phase 2	Bevacizumab
37	Phase II Trial of Combined Modality Combretastatin A-4 Phosphate (CA4P)-Based Therapy for Patients With Newly Diagnosed Anaplastic Thyroid Cancer [Induction Chemotherapy With Doxorubicin/Cisplatin; Combined Modality Therapy With CA4P and Radiation; Followed by 2 Cycles of CA4P Consolidation]	Terminated	NCT00077103	Phase 1, Phase 2	cisplatin;doxorubicin hydrochloride;fosbretabulin disodium
38	Phase II Trial Evaluating Gleevec (Imatinib Mesylate Formerly Known as STI571) in Patients With Anaplastic Thyroid Cancer	Terminated	NCT00115739	Phase 2	Imatinib
39	A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel in Subjects With Advanced Anaplastic Thyroid Cancer	Terminated	NCT00603941	Phase 1, Phase 2	CS-7017;Paclitaxel
40	Phase II Trial of BAY 43-9006 in Patients With Advanced Anaplastic Carcinoma of the Thyroid	Terminated	NCT00126568	Phase 2	sorafenib tosylate
41	Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma	Terminated	NCT00095693	Phase 2	sorafenib tosylate
42	A Phase II Trial of CUDC-907 in Patients With Metastatic and Locally Advanced Thyroid Cancer	Terminated	NCT03002623	Phase 2	CUDC-907
43	Ceritinib in Mutation and Oncogene Directed Therapy in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer	Withdrawn	NCT02289144	Phase 2	Ceritinib
44	A Pilot Study of Durvalumab (MEDI4736) With Tremelimumab in Combination With Image Guided Stereotactic Body Radiotherapy (SBRT) in the Treatment of Metastatic Anaplastic Thyroid Cancer	Completed	NCT03122496	Phase 1	durvalumab;tremelimumab
45	A Phase I Trial of Herceptin and Interleukin-12	Completed	NCT00004074	Phase 1
46	A Multi Center Phase I Study of AIC100 in Relapsed and/or Refractory Advanced Thyroid Cancer and Anaplastic Thyroid Cancer	Recruiting	NCT04420754	Phase 1
47	A Phase I Trial of Concurrent Intensity Modulated Radiation Therapy (IMRT) and Dabrafenib/Trametinib in BRAF Mutated Anaplastic Thyroid Cancer	Suspended	NCT03975231	Phase 1	Dabrafenib;Trametinib
48	A Phase I Trial Assessing Adalimumab (Humira®), a Tumor Necrosis Factor α Inhibitor Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers	Withdrawn	NCT02516774	Phase 1	Adalimumab
49	A Retrospective Review of Multimodality Management of Anaplastic Thyroid Cancer	Completed	NCT00280852
50	Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients	Completed	NCT02862470

Search NIH Clinical Center for Thyroid Gland Anaplastic Carcinoma

Sources

Genetic Tests for Thyroid Gland Anaplastic Carcinoma

Sources

Anatomical Context for Thyroid Gland Anaplastic Carcinoma

Organs/tissues related to Thyroid Gland Anaplastic Carcinoma:

MalaCards : Thyroid, Lymph Node, Bone, Lung, Skeletal Muscle, Endothelial, Breast

Sources

Publications for Thyroid Gland Anaplastic Carcinoma

Articles related to Thyroid Gland Anaplastic Carcinoma:

(show top 50) (show all 2322)

#	Title	Authors	PMID	Year
1	Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. ⁶² ⁴⁶	Takakura S...Yamashita S	18429962	2008
2	High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. ⁵	Fagin JA...Koeffler HP	8423216	1993
3	Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. ⁵	Malkin D...Garber J	1565144	1992
4	Hsa-miR-34c suppresses growth and invasion of human laryngeal carcinoma cells via targeting c-Met. ⁴⁶	Cai KM...Zhao XJ	20198305	2010
5	Wild-type p53 enhances the cytotoxic effect of radionuclide gene therapy using sodium iodide symporter in a murine anaplastic thyroid cancer model. ⁵³ ⁶²	Lee YJ...Lee MC	19727716	2010
6	Mutant p53 (G199V) gains antiapoptotic function through signal transducer and activator of transcription 3 in anaplastic thyroid cancer cells. ⁵³ ⁶²	Kim TH...Yoo YH	19825993	2009
7	Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition. ⁵³ ⁶²	Schweppe RE...Haugen BR	19500021	2009
8	R-roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-kappaB pathway. ⁵³ ⁶²	Festa M...Parente L	19230027	2009
9	Anaplastic thyroid cancer: prevalence, diagnosis and treatment. ⁵³ ⁶²	Chiacchio S...Mariani G	18923370	2008
10	Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. ⁵³ ⁶²	Hou P...Xing M	18831514	2008
11	Peroxisome proliferator-activated receptor gamma inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner. ⁵³ ⁶²	Bonofiglio D...Ando S	18509005	2008
12	Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. ⁵³ ⁶²	Paes JE...Ringel MD	18502332	2008
13	HDAC6 is required for epidermal growth factor-induced beta-catenin nuclear localization. ⁵³ ⁶²	Li Y...Comb MJ	18356165	2008
14	BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. ⁵³ ⁶²	Sala E...Gambacorti-Passerini C	18458053	2008
15	Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. ⁵³ ⁶²	Abubaker J...Al-Kuraya KS	18000091	2008
16	Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. ⁵³ ⁶²	Ball DW...Nelkin BD	17878251	2007
17	Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. ⁴⁶	Visone R...Fusco A	17563749	2007
18	[Gene abnormalities in thyroid cancer]. ⁵³ ⁶²	Namba H...Yamashita S	18018556	2007
19	[Molecular mechanism of thyroid carcinogenesis]. ⁵³ ⁶²	Yamashita S...Mitsutake N	18018555	2007
20	Quantitative measurement of telomerase reverse transcriptase, thyroglobulin and thyroid transcription factor 1 mRNAs in anaplastic thyroid carcinoma tissues and cell lines. ⁵³ ⁶²	Takano T...Miyauchi A	17671725	2007
21	Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. ⁵³ ⁶²	Conticello C...De Maria R	17327374	2007
22	A conditionally replicative, Wnt/beta-catenin pathway-based adenovirus therapy for anaplastic thyroid cancer. ⁵³ ⁶²	Abbosh PH...Nephew KP	17218945	2007
23	Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. ⁵³ ⁶²	Aiello A...Belfiore A	16777971	2006
24	Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma. ⁵³ ⁶²	Wang Z...Myers JN	16899627	2006
25	Antisense p53 decreases production of VEGF in follicular thyroid cancer cells. ⁵³ ⁶²	Hassan I...Zielke A	16943578	2006
26	Ribonucleic acid interference targeting S100A4 (Mts1) suppresses tumor growth and metastasis of anaplastic thyroid carcinoma in a mouse model. ⁵³ ⁶²	Shi Y...Al-Mohanna FA	16551737	2006
27	Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. ⁵³ ⁶²	Wiseman SM...Gilks B	16647341	2006
28	Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. ⁵³ ⁶²	Copland JA...Smallridge RC	16331265	2006
29	BRAF is a therapeutic target in aggressive thyroid carcinoma. ⁵³ ⁶²	Salvatore G...Santoro M	16533790	2006
30	Redox control of manumycin A-induced apoptosis in anaplastic thyroid cancer cells: involvement of the xenobiotic apoptotic pathway. ⁵³ ⁶²	She M...Yeung SC	16410725	2006
31	Wnt/beta-catenin signaling mediates antineoplastic effects of imatinib mesylate (gleevec) in anaplastic thyroid cancer. ⁵³ ⁶²	Rao AS...Brabant G	16263821	2006
32	Differential effects of TGF-beta1 on telomerase activity in thyroid carcinoma cell lines. ⁵³ ⁶²	Lindkvist A...Paulsson-Karlsson Y	16288728	2005
33	Altered gene expression profiles by sodium/iodide symporter gene transfection in a human anaplastic thyroid carcinoma cell line using a radioactive complementary DNA microarray. ⁵³ ⁶²	Gol Choe J...Kim MK	16264365	2005
34	Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma. ⁵³ ⁶²	Bravo SB...Alvarez CV	16278386	2005
35	S100A4 (Mts1) gene overexpression is associated with invasion and metastasis of papillary thyroid carcinoma. ⁵³ ⁶²	Zou M...Shi Y	16265347	2005
36	Mutation of the PIK3CA gene in anaplastic thyroid cancer. ⁵³ ⁶²	Garcia-Rostan G...Santoro M	16288007	2005
37	Reverse transcriptase inhibitors down-regulate cell proliferation in vitro and in vivo and restore thyrotropin signaling and iodine uptake in human thyroid anaplastic carcinoma. ⁵³ ⁶²	Landriscina M...Cignarelli M	16030158	2005
38	RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors. ⁵³ ⁶²	Nakamura N...Lloyd RV	15980887	2005
39	Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. ⁵³ ⁶²	Younes MN...Myers JN	16093430	2005
40	Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene. ⁵³ ⁶²	Presta I...Russo D	16029487	2005
41	Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. ⁵³ ⁶²	Quiros RM...Xu X	15880523	2005
42	Modulation of retrovirally driven therapeutic genes by mutant TP53 in anaplastic thyroid carcinoma. ⁵³ ⁶²	Barzon L...Palu G	15650765	2005
43	Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. ⁵³ ⁶²	Nobuhara Y...Hirakawa K	15785737	2005
44	Advances in the management of thyroid cancer. ⁵³ ⁶²	Shaha AR	17462286	2005
45	BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. ⁵³ ⁶²	Begum S...Westra WH	15195111	2004
46	Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. ⁵³ ⁶²	Furuya F...Kobayashi T	14976143	2004
47	Antitumor effects of peroxisome proliferator activate receptor gamma ligands on anaplastic thyroid carcinoma. ⁵³ ⁶²	Hayashi N...Monden M	14654945	2004
48	[Genetic causes of the thyroid carcinomas]. ⁵³ ⁶²	Jindrichova S...Bendlova B	15584614	2004
49	Gadd45gamma expression is reduced in anaplastic thyroid cancer and its reexpression results in apoptosis. ⁵³ ⁶²	Chung HK...Shong M	12915687	2003
50	Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. ⁵³ ⁶²	Wang CY...Tsai YF	12843138	2003

Sources

Genes for Thyroid Gland Anaplastic Carcinoma

Genes related to Thyroid Gland Anaplastic Carcinoma (5 elite genes):

(show top 50) (show all 78)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	TP53	Tumor Protein P53	Protein Coding	414.54	Pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1565144 8423216 12364480 (more) 9038381 15650765 12370767 16943578 19199318 19727716 8631011 11820615 8612724 15584614 18018556 7629382 9247627 7640449 17131411 11902457 8620454 18018555 10634403 9768682 19825993 11838727 10646883 8195930 16278386 12915687 15689324 15880523 12642691 1483945
2	MIR17	MicroRNA 17	RNA Gene	357.93	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18429962
3	MIR19A	MicroRNA 19a	RNA Gene	353.79	Causal ⁴⁶ DISEASES inferred ¹⁴	18429962
4	MIR18A	MicroRNA 18a	RNA Gene	353.5	Causal ⁴⁶ DISEASES inferred ¹⁴	18429962
5	MIR34C	MicroRNA 34c	RNA Gene	353.24	Causal ⁴⁶ DISEASES inferred ¹⁴	20198305
6	MIR30D	MicroRNA 30d	RNA Gene	55.28	Unspecified ⁴⁶ DISEASES inferred ¹⁴	17563749
7	MIR30A	MicroRNA 30a	RNA Gene	54.87	Unspecified ⁴⁶ DISEASES inferred ¹⁴	17563749
8	TG	Thyroglobulin	Protein Coding	17.55	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15650765 1712540 11325833 (more) 8157713 12843138 17671725 18923370 14976143 16030158
9	PAX8	Paired Box 8	Protein Coding	16.37	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11325833 15650356 16029487
10	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	15.6	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15195111 16533790 15880523 (more) 17878251 15001635 18458053 15980887 18070147 19500021 14602780 19879919
11	NKX2-1	NK2 Homeobox 1	Protein Coding	15.45	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11325833 1726928 17671725 (more) 11014583
12	RET	Ret Proto-Oncogene	Protein Coding	15.45	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17462286 8319199 15841388
13	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	14.15	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16288007 15928251 18000091 (more) 18502332
14	PTEN	Phosphatase And Tensin Homolog	Protein Coding	13.52	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18831514 10793080 11159944
14	PTEN::MIR19A ⁴⁶	MIR19A Macro RNA (hsa-miR-19a) targets PTEN
15	TPO	Thyroid Peroxidase	Protein Coding	12.88	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1712540 8157713 8631011 (more) 16030158
16	CALCA	Calcitonin Related Polypeptide Alpha	Protein Coding	12.26	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1712540 1694984
17	TSHR	Thyroid Stimulating Hormone Receptor	Protein Coding	12.24	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8892315 8157713 10646883
18	CDH1	Cadherin 1	Protein Coding	12.11	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16647341 10521809
19	ADGRE5	Adhesion G Protein-Coupled Receptor E5	Protein Coding	12.03	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10084602
20	CTNNB1	Catenin Beta 1	Protein Coding	11.48	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10213482 17218945 16647341 (more) 18356165 16263821 17131411
21	CDKN1A	Cyclin Dependent Kinase Inhibitor 1A	Protein Coding	11.45	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12574211 12716888
22	PPARG	Peroxisome Proliferator Activated Receptor Gamma	Protein Coding	11.45	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12495476 16331265 16029127 (more) 12161538 14654945 16777971 18509005
23	TERT	Telomerase Reverse Transcriptase	Protein Coding	10.99	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12915632 17671725
24	LGALS3	Galectin 3	Protein Coding	10.69	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19199318
25	MET	MET Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	10.43	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10942601 10487693
25	MET::MIR34C ⁴⁶	MIR34C Macro RNA (hsa-miR-34c) targets MET
26	CASP3	Caspase 3	Protein Coding	10.19	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11600533
27	SLC26A4	Solute Carrier Family 26 Member 4	Protein Coding	9.97	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12727855
28	S100A4	S100 Calcium Binding Protein A4	Protein Coding	9.9	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16551737 16265347
29	EGF	Epidermal Growth Factor	Protein Coding	9.52	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15785737 14679016
30	MIR222	MicroRNA 222	RNA Gene	9.3	DISEASES inferred ¹⁴ ¹⁴
31	MIR138-1	MicroRNA 138-1	RNA Gene	9.03	DISEASES inferred ¹⁴ ¹⁴
32	MIR146B	MicroRNA 146b	RNA Gene	8.92	DISEASES inferred ¹⁴ ¹⁴
33	TNFSF10	TNF Superfamily Member 10	Protein Coding	8.62	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19230027 17327374 14647456 (more) 19190106
34	BCL2L1	BCL2 Like 1	Protein Coding	8.55	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	14583474
35	MAPK1	Mitogen-Activated Protein Kinase 1	Protein Coding	8.24	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19500021
36	ILK	Integrin Linked Kinase	Protein Coding	7.72	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16093430
37	CYCS	Cytochrome C, Somatic	Protein Coding	7.66	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11600533 16410725
38	CASP8	Caspase 8	Protein Coding	7.57	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11600533
39	MIR144	MicroRNA 144	RNA Gene	7.5	DISEASES inferred ¹⁴ ¹⁴
40	TGFB1	Transforming Growth Factor Beta 1	Protein Coding	7.3	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19645615 10459856 16288728 (more) 12432546
41	MIR200A	MicroRNA 200a	RNA Gene	7.27	DISEASES inferred ¹⁴ ¹⁴
42	MIR145	MicroRNA 145	RNA Gene	7.26	DISEASES inferred ¹⁴ ¹⁴
43	MIR183	MicroRNA 183	RNA Gene	7.22	DISEASES inferred ¹⁴ ¹⁴
44	MIRLET7G	MicroRNA Let-7g	RNA Gene	7.19	DISEASES inferred ¹⁴ ¹⁴
45	TPCN1	Two Pore Segment Channel 1	Protein Coding	7.15	DISEASES inferred ¹⁴
46	MIR370	MicroRNA 370	RNA Gene	6.96	DISEASES inferred ¹⁴ ¹⁴
47	MIR101-1	MicroRNA 101-1	RNA Gene	6.9	DISEASES inferred ¹⁴ ¹⁴
48	MIR199A1	MicroRNA 199a-1	RNA Gene	6.71	DISEASES inferred ¹⁴ ¹⁴
49	MIR181A1	MicroRNA 181a-1	RNA Gene	6.69	DISEASES inferred ¹⁴ ¹⁴
50	IGF1R	Insulin Like Growth Factor 1 Receptor	Protein Coding	6.65	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16899627

Sources

Variations for Thyroid Gland Anaplastic Carcinoma

ClinVar genetic disease variations for Thyroid Gland Anaplastic Carcinoma:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	TP53	NM_000546.6(TP53):c.818G>A (p.Arg273His)	SNV	Pathogenic	12366	rs28934576	GRCh37: 17:7577120-7577120 GRCh38: 17:7673802-7673802

Cosmic variations for Thyroid Gland Anaplastic Carcinoma:

⁸ (show top 50) (show all 5257)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM90416635	ZNF703	thyroid,NS,carcinoma,anaplastic carcinoma	c.1232C>T	p.A411V	8:37698133-37698133	17
2	COSM84513642	ZNF276	thyroid,NS,carcinoma,anaplastic carcinoma	c.*2596A>T	p.?	16:89740842-89740842	17
3	COSM101980343	XPO1	thyroid,NS,carcinoma,anaplastic carcinoma	c.1353A>G	p.I451M	2:61492946-61492946	17
4	COSM104240109	XPO1	thyroid,NS,carcinoma,anaplastic carcinoma	c.1353A>G	p.I451M	2:61492946-61492946	17
5	COSM104886876	XPO1	thyroid,NS,carcinoma,anaplastic carcinoma	c.1353A>G	p.I451M	2:61492946-61492946	17
6	COSM90659403	VHL	thyroid,NS,carcinoma,anaplastic carcinoma	c.289C>T	p.P97S	3:10142136-10142136	17
7	COSM88298168	VHL	thyroid,NS,carcinoma,anaplastic carcinoma	c.289C>T	p.P97S	3:10142136-10142136	17
8	COSM116191954	UQCC5	thyroid,NS,carcinoma,anaplastic carcinoma	c.152-14856G>C	p.?	3:52564162-52564162	17
9	COSM116186743	UQCC5	thyroid,NS,carcinoma,anaplastic carcinoma	c.152-17231G>C	p.?	3:52561787-52561787	17
10	COSM102449047	U2AF1	thyroid,NS,carcinoma,anaplastic carcinoma	c.28G>C	p.E10Q	21:43095696-43095696	17
11	COSM99372056	U2AF1	thyroid,NS,carcinoma,anaplastic carcinoma	c.247G>C	p.E83Q	21:43095696-43095696	17
12	COSM112017925	U2AF1	thyroid,NS,carcinoma,anaplastic carcinoma	c.78G>A	p.M26I	21:43095489-43095489	17
13	COSM99368161	U2AF1	thyroid,NS,carcinoma,anaplastic carcinoma	c.297G>A	p.M99I	21:43095489-43095489	17
14	COSM112020403	U2AF1	thyroid,NS,carcinoma,anaplastic carcinoma	c.28G>C	p.E10Q	21:43095696-43095696	17
15	COSM85196814	U2AF1	thyroid,NS,carcinoma,anaplastic carcinoma	c.247G>C	p.E83Q	21:43095696-43095696	17
16	COSM85193419	U2AF1	thyroid,NS,carcinoma,anaplastic carcinoma	c.297G>A	p.M99I	21:43095489-43095489	17
17	COSM102445292	U2AF1	thyroid,NS,carcinoma,anaplastic carcinoma	c.78G>A	p.M26I	21:43095489-43095489	17
18	COSM86824282	TYRO3	thyroid,NS,carcinoma,anaplastic carcinoma	c.2194C>T	p.P732S	15:41573727-41573727	17
19	COSM135709676	TYRO3	thyroid,NS,carcinoma,anaplastic carcinoma	c.2059C>T	p.P687S	15:41573727-41573727	17
20	COSM131092631	TSHR	thyroid,NS,carcinoma,anaplastic carcinoma	c.1672G>A	p.V558M	14:81143730-81143730	17
21	COSM85466293	TSHR	thyroid,NS,carcinoma,anaplastic carcinoma	c.1703T>C	p.I568T	14:81143761-81143761	17
22	COSM85466972	TSHR	thyroid,NS,carcinoma,anaplastic carcinoma	c.1789G>C	p.V597L	14:81143847-81143847	17
23	COSM85466282	TSHR	thyroid,NS,carcinoma,anaplastic carcinoma	c.1514G>A	p.S505N	14:81143572-81143572	17
24	COSM131089965	TSHR	thyroid,NS,carcinoma,anaplastic carcinoma	c.1911G>T	p.M637I	14:81143969-81143969	17
25	COSM85472824	TSHR	thyroid,NS,carcinoma,anaplastic carcinoma	c.1911G>T	p.M637I	14:81143969-81143969	17
26	COSM85469801	TSHR	thyroid,NS,carcinoma,anaplastic carcinoma	c.842G>C	p.S281T	14:81139828-81139828	17
27	COSM131087195	TSHR	thyroid,NS,carcinoma,anaplastic carcinoma	c.842G>C	p.S281T	14:81139828-81139828	17
28	COSM85475366	TSHR	thyroid,NS,carcinoma,anaplastic carcinoma	c.1672G>A	p.V558M	14:81143730-81143730	17
29	COSM131089960	TSHR	thyroid,NS,carcinoma,anaplastic carcinoma	c.1898A>C	p.D633A	14:81143956-81143956	17
30	COSM131083598	TSHR	thyroid,NS,carcinoma,anaplastic carcinoma	c.1703T>C	p.I568T	14:81143761-81143761	17
31	COSM131084149	TSHR	thyroid,NS,carcinoma,anaplastic carcinoma	c.1789G>C	p.V597L	14:81143847-81143847	17
32	COSM85472813	TSHR	thyroid,NS,carcinoma,anaplastic carcinoma	c.1898A>C	p.D633A	14:81143956-81143956	17
33	COSM131083592	TSHR	thyroid,NS,carcinoma,anaplastic carcinoma	c.1514G>A	p.S505N	14:81143572-81143572	17
34	COSM101185486	TSC2	thyroid,NS,carcinoma,anaplastic carcinoma	c.1292A>G	p.Y431C	16:2063049-2063049	17
35	COSM151512883	TSC2	thyroid,NS,carcinoma,anaplastic carcinoma	c.5038G>A	p.D1680N	16:2088092-2088092	17
36	COSM150313015	TSC2	thyroid,NS,carcinoma,anaplastic carcinoma	c.4912G>A	p.D1638N	16:2088092-2088092	17
37	COSM147690582	TSC2	thyroid,NS,carcinoma,anaplastic carcinoma	c.4984G>A	p.D1662N	16:2088092-2088092	17
38	COSM151380590	TSC2	thyroid,NS,carcinoma,anaplastic carcinoma	c.793G>T	p.G265C	16:2057123-2057123	17
39	COSM110102153	TSC2	thyroid,NS,carcinoma,anaplastic carcinoma	c.4804G>A	p.D1602N	16:2088092-2088092	17
40	COSM147690543	TSC2	thyroid,NS,carcinoma,anaplastic carcinoma	c.229G>A	p.A77T	16:2053345-2053345	17
41	COSM149800713	TSC2	thyroid,NS,carcinoma,anaplastic carcinoma	c.229G>A	p.A77T	16:2053345-2053345	17
42	COSM151746971	TSC2	thyroid,NS,carcinoma,anaplastic carcinoma	c.229G>A	p.A77T	16:2053345-2053345	17
43	COSM110124471	TSC2	thyroid,NS,carcinoma,anaplastic carcinoma	c.682G>T	p.G228C	16:2057123-2057123	17
44	COSM149823983	TSC2	thyroid,NS,carcinoma,anaplastic carcinoma	c.793G>T	p.G265C	16:2057123-2057123	17
45	COSM150574934	TSC2	thyroid,NS,carcinoma,anaplastic carcinoma	c.4906G>A	p.D1636N	16:2088092-2088092	17
46	COSM90402476	TSC2	thyroid,NS,carcinoma,anaplastic carcinoma	c.5044G>A	p.D1682N	16:2088092-2088092	17
47	COSM151370140	TSC2	thyroid,NS,carcinoma,anaplastic carcinoma	c.229G>A	p.A77T	16:2053345-2053345	17
48	COSM87033564	TSC2	thyroid,NS,carcinoma,anaplastic carcinoma	c.1439A>G	p.Y480C	16:2063049-2063049	17
49	COSM87027114	TSC2	thyroid,NS,carcinoma,anaplastic carcinoma	c.229G>A	p.A77T	16:2053345-2053345	17
50	COSM149807155	TSC2	thyroid,NS,carcinoma,anaplastic carcinoma	c.1439A>G	p.Y480C	16:2063049-2063049	17

Copy number variations for Thyroid Gland Anaplastic Carcinoma from CNVD:

⁶ (show all 18)

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	18562	1	146514610	148102224	Gain		Anaplastic thyroid cancer
2	57418	11	63321142	66212707	Gain	CCND1	Anaplastic thyroid cancer
3	68082	12	47384342	48639263	Gain		Anaplastic thyroid cancer
4	78984	13	61113549	63481793	Loss		Anaplastic thyroid cancer
5	99673	16	28082639	28922556	Gain		Anaplastic thyroid cancer
6	114238	17	45949240	46466966	Gain		Anaplastic thyroid cancer
7	124653	19	11950033	12150103	Gain		Anaplastic thyroid cancer
8	128382	19	40542097	41211643	Gain		Anaplastic thyroid cancer
9	152529	20	31497814	33184582	Gain		Anaplastic thyroid cancer
10	153944	20	41887694	44153298	Gain	UBE2C	Anaplastic thyroid cancer
11	161614	22	19538297	19939137	Gain		Anaplastic thyroid cancer
12	164302	22	36003989	36444264	Gain		Anaplastic thyroid cancer
13	171639	3	170900000	182700000	Copy number	PIK3CA	Anaplastic thyroid cancer
14	182004	4	132076562	133123563	Loss		Anaplastic thyroid cancer
15	188265	4	61317501	66095641	Loss		Anaplastic thyroid cancer
16	211600	6	33165527	33494594	Gain		Anaplastic thyroid cancer
17	225370	7	45400000	54000000	Amplification	EGFR	Anaplastic thyroid cancer
18	227803	7	72035816	72259198	Gain		Anaplastic thyroid cancer

Sources

Expression for Thyroid Gland Anaplastic Carcinoma

Search GEO for disease gene expression data for Thyroid Gland Anaplastic Carcinoma.

Sources

Pathways for Thyroid Gland Anaplastic Carcinoma

Pathways related to Thyroid Gland Anaplastic Carcinoma according to GeneCards Suite gene sharing:

(show all 35)

#	Super pathways	Score	Top Affiliating Genes
1	Signal Transduction ⁶⁶	13.62	TSHR TP53 RET PTEN PIK3CA CTNNB1
2	Malignant pleural mesothelioma ⁷⁴	12.6	TP53 PTEN PIK3CA CTNNB1 CDH1
3	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.42	TP53 PTEN PIK3CA CTNNB1 CDH1 BRAF
4	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.32	TP53 PIK3CA CTNNB1 CDH1 BRAF
5	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.31	TP53 PTEN PIK3CA CTNNB1 BRAF
6	Focal adhesion ⁷⁴	12.21	BRAF CTNNB1 PIK3CA PTEN
7	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.14	TP53 PTEN PIK3CA BRAF
8	Colorectal Cancer Metastasis ⁶⁴	12.08	TP53 CTNNB1 CDH1 BRAF
9	Epithelial to mesenchymal transition in colorectal cancer ⁷⁴	12.06	TP53 PIK3CA CTNNB1 CDH1
10	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	11.86	TP53 PTEN PIK3CA CTNNB1 CDH1 BRAF
11	Small cell lung cancer ⁷⁴	11.82	TP53 PTEN PIK3CA
12	DNA damage response (only ATM dependent) ⁷⁴	11.77	TP53 PTEN PIK3CA CTNNB1
13	Integrated breast cancer pathway ⁷⁴	11.73	TP53 PTEN CTNNB1 CDH1 BRAF
14	VEGF Pathway (Tocris) ⁷⁰ Show member pathways Sorafenib Pharmacodynamics ⁶⁰	11.72	RET PIK3CA BRAF
15	Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ⁶¹	11.66	PIK3CA CTNNB1 CDH1
16	AP-1 transcription factor network ⁶¹	11.65	TP53 PTEN CTNNB1
17	Signaling events mediated by VEGFR1 and VEGFR2 ⁶¹	11.6	PIK3CA CTNNB1 BRAF
18	Pathways affected in adenoid cystic carcinoma ⁷⁴	11.59	TP53 PTEN PIK3CA
19	Thyroid hormones production and peripheral downstream signaling effects ⁷⁴	11.59	TSHR TP53 PIK3CA CTNNB1
20	Thyroid stimulating hormone (TSH) signaling pathway ⁷⁴	11.54	TSHR PIK3CA BRAF
21	Copper homeostasis ⁷⁴ Show member pathways Copper metabolism ⁷⁴ Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1) ⁶⁶	11.54	TP53 PTEN PIK3CA
22	IL-18 signaling pathway ⁷⁴	11.46	TP53 PTEN CTNNB1
23	Posttranslational regulation of adherens junction stability and dissassembly ⁶¹	11.43	RET CTNNB1 CDH1
24	Arf6 trafficking events ⁶¹	11.42	TSHR CTNNB1 CDH1
25	Head and neck squamous cell carcinoma ⁷⁴	11.42	TP53 PTEN PIK3CA CTNNB1
26	Bladder cancer ⁷⁴	11.31	BRAF CDH1 TP53
27	E-cadherin signaling in the nascent adherens junction ⁶¹ Show member pathways AlphaE beta7 integrin cell surface interactions ⁶¹	11.28	PIK3CA CTNNB1 CDH1
28	Nectin adhesion pathway ⁶¹	11.12	PIK3CA CTNNB1 CDH1
29	Thyroxine (thyroid hormone) production ⁷⁴	10.88	TG TPO TSHR
30	miRNAs involved in DNA damage response ⁷⁴	10.85	TP53 MIR34C MIR19A MIR18A MIR17
31	H19 action Rb-E2F1 signaling and CDK-Beta-catenin activity ⁷⁴	10.81	CTNNB1 CDH1
32	TCA cycle in senescence ⁷⁴	10.65	TP53 BRAF
33	Relationship between inflammation, COX-2 and EGFR ⁷⁴	10.65	PIK3CA BRAF
34	Mammary gland development pathway - Involution (Stage 4 of 4) ⁷⁴	10.65	TP53 CDH1
35	Regorafenib Pathway, Pharmacodynamics ⁶⁰	10.53	RET BRAF

Sources

GO Terms for Thyroid Gland Anaplastic Carcinoma

Cellular components related to Thyroid Gland Anaplastic Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular vesicle	GO:1903561	8.92	MIR30D MIR30A MIR19A MIR17

Biological processes related to Thyroid Gland Anaplastic Carcinoma according to GeneCards Suite gene sharing:

(show all 12)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	10.25	TP53 RET NKX2-1 MIR17 CTNNB1 BRAF
2	negative regulation of gene expression	GO:0010629	10.02	TP53 PIK3CA MIR19A MIR17 CTNNB1
3	T cell differentiation in thymus	GO:0033077	9.91	TP53 CTNNB1 BRAF
4	negative regulation of transforming growth factor beta receptor signaling pathway	GO:0030512	9.8	TP53 NKX2-1 MIR18A MIR17
5	endothelial cell migration	GO:0043542	9.77	PTEN PIK3CA CALCA
6	cellular response to indole-3-methanol	GO:0071681	9.71	CDH1 CTNNB1
7	vasculature development	GO:0001944	9.56	PIK3CA CTNNB1 CALCA
8	thyroid gland development	GO:0030878	9.56	TG PAX8 NKX2-1 BRAF
9	regulation of axon regeneration	GO:0048679	9.49	PTEN BRAF
10	positive regulation of cardiac muscle hypertrophy in response to stress	GO:1903244	9.46	MIR34C MIR17
11	thyroid-stimulating hormone signaling pathway	GO:0038194	9.46	TSHR PAX8
12	negative regulation of sprouting angiogenesis	GO:1903671	8.92	MIR34C MIR19A MIR18A MIR17

Molecular functions related to Thyroid Gland Anaplastic Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA 3'-UTR binding	GO:0003730	9.5	TP53 MIR34C MIR30D MIR30A MIR19A MIR17
2	thyroid-stimulating hormone receptor activity	GO:0004996	9.46	TSHR PAX8
3	mRNA base-pairing translational repressor activity	GO:1903231	9.1	MIR34C MIR30D MIR30A MIR19A MIR18A MIR17